KG and FHS contributed equally to this work.
BLOOD MANAGEMENT IN THE OPERATING ROOM
Coagulation management with factor concentrates in liver transplantation: a single-center experience
Article first published online: 14 MAY 2014
© 2014 AABB
Special Issue: The evolving paradigm of patient blood management
Volume 54, Issue 10pt2, pages 2760–2768, October 2014
How to Cite
Kirchner, C., Dirkmann, D., Treckmann, J. W., Paul, A., Hartmann, M., Saner, F. H. and Görlinger, K. (2014), Coagulation management with factor concentrates in liver transplantation: a single-center experience. Transfusion, 54: 2760–2768. doi: 10.1111/trf.12707
Funded by CSL Behring.
- Issue published online: 10 OCT 2014
- Article first published online: 14 MAY 2014
- Manuscript Accepted: 4 FEB 2014
- Manuscript Revised: 27 JAN 2014
- Manuscript Received: 17 OCT 2013
- CSL Behring
Allogeneic blood products transfusion during liver transplantation (LT) can be associated with increased morbidity and mortality. Data on thromboelastometry (ROTEM)-guided coagulation management with coagulation factor concentrates (CFCs)—fibrinogen concentrate and/or prothrombin complex concentrate (PCC)—are sparse. We aimed to retrospectively evaluate the safety events observed with this approach in our clinic.
Study Design and Methods
LT patients from January 2009 to December 2010 (n = 266) were identified by chart review. A ROTEM-based algorithm with CFC guided the hemostatic therapy. Doppler ultrasound was used to evaluate thrombosis in the hepatic artery, portal vein, and hepatic veins. Stroke, myocardial ischemia, pulmonary embolism, and transfusion variables were recorded. Patients receiving CFC were included in the CFC group (n = 156); those not receiving CFC were included in the non-CFC group (n = 110). Safety events were compared between these two groups.
Allogeneic transfusion(s) in the 266 patients was low, with medians of 2 (interquartile range [IQR], 0-5), 0 (IQR 0-0), and 0 (IQR 0-1) units for red blood cells (RBCs), fresh-frozen plasma (FFP), and platelets (PLTs), respectively. Ninety-seven of 266 LTs (36.5%) were performed without RBCs transfusion, 227 (85.3%) without FFP, and 190 (71.4%) without PLTs. There were no significant differences in thrombotic, thromboembolic, and ischemic adverse events occurrence between the CFC group and the non-CFC group (11/156 patients vs. 5/110; p = 0.31).
In LT, ROTEM-guided treatment with fibrinogen concentrate and/or PCC did not appear to increase the occurrence of thrombosis and ischemic events compared to patients who did not receive these concentrates.